All In Biotech

Drug Trial Radar · NCT03018730

Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

An Open Label Study of the Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa)

Last checked: Nov 20, 2026Latest source record: Sep 13, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

22

Actual

Start

May 17, 2017

Primary completion

Dec 17, 2019

Study completion Jan 9, 2020

Sponsor

Lead sponsor
ProtalixIndustry
Sponsor type
Industry
Collaborators
Chiesi Farmaceutici S.p.A.
First posted
Jan 12, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 60 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label switch over study to assess the safety and efficacy of PRX-102 (pegunigalsidase alfa). Patients treated with agalsidase alfa for at least 2 years and on a stable dose (\>80% labelled dose/kg) for at least 6 months. Patients will be screened and evaluated over 3 months while continuing on agalsidase alfa. Following the screening period, the patient will be enrolled and switched from their agalsidase alfa treatment to receive intravenous (IV) infusions of PRX-102 1 mg/kg every two weeks for 12 months. No more than 25% of treated patients will be female.

Conditions

  • Fabry Disease

Interventions

  • PRX-102 (pegunigalsidase alfa)Biological

    PRX-102 1 mg/kg every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.03Time frame: 12 months

Locations

9 sites in 7 countries. Site status is shown where the registry gives one.

  • Royal Melbourne Hospital

    Parkville, Victoria, Australia

  • Capital Health

    Halifax, Nova Scotia, Canada

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • Academisch Medisch Centrum

    Amsterdam, Netherlands

  • Helse Bergen HF Haukeland Universitetssykehus

    Bergen, Norway

  • General Hospital Slovenj Gradec

    Slovenj Gradec, Slovenia

  • The Royal Free Hospital

    London, United Kingdom

  • Salford Royal NHS Foundation Trust

    Salford, United Kingdom

  • Queen Elizabeth Hospital, Department of Neurology,

    Edgbaston, Birmingham, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.